LifeStance Health Group, Inc. LFST
Unless stated otherwise or the context otherwise requires, the terms "we," "us," "our," "our business," "LifeStance" and "our Company" and similar references refer to LifeStance Health Group, Inc. and its consolidated subsidiaries and supported practices. References to "our employees" and "our clinicians" refer collectively to employees and clinicians, respectively, of our subsidiaries and supported practices. References to "our patients" refer to the patients treated by such clinicians.
Our vision is a truly healthy society where mental and physical healthcare are unified to make lives better. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. To fulfill this mission, we have built one of the nation's largest outpatient mental health platforms based on number of clinicians and geographic scale.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.42B | $1.25B | $1.06B | $859.5M | $667.5M | — | $212.5M | — |
| SG&A | $382.2M | $363.1M | $410.8M | $378.0M | $433.7M | — | $41.1M | — |
| Total operating expenses | $1.40B | $1.28B | $1.24B | $1.07B | $953.9M | — | $197.3M | — |
| Operating income | $24.1M | -$31.6M | -$189.1M | -$210.2M | -$286.4M | — | $15.2M | — |
| Interest expense | $11.7M | $26.5M | $21.2M | $19.9M | $38.9M | — | $5.4M | — |
| Pre-tax income | $12.4M | -$57.6M | -$206.6M | -$232.7M | -$333.1M | — | $7.9M | — |
| Income tax | $2.7M | $170.0K | $20.3M | $17.2M | $25.9M | — | $2.2M | — |
| Net income | $9.7M | -$57.4M | -$186.3M | -$215.6M | -$307.2M | — | $5.7M | — |
| Shares, diluted (wtd. avg.) | $391.1M | $379.1M | $367.5M | $355.3M | $327.5K | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $248.6M | $154.6M | $78.8M | $108.6M | $148.0M | $18.8M | $3.5M | $11.3M |
| Receivables | $95.7M | $131.8M | $125.4M | $100.9M | $76.1M | $43.7M | — | — |
| Total current assets | $416.2M | $312.5M | $225.7M | $233.2M | $266.5M | $76.3M | — | — |
| Property, plant and equipment | $161.6M | $166.0M | $188.2M | $194.2M | $152.2M | $59.3M | — | — |
| Goodwill | $1.29B | $1.29B | $1.29B | $1.27B | $1.20B | $1.10B | $926.7M | — |
| Other intangibles | $177.7M | $190.8M | $221.1M | $263.3M | $300.4M | $332.8M | — | — |
| Total assets | $2.20B | $2.12B | $2.11B | $2.17B | $1.93B | $1.57B | — | — |
| Accounts payable | $6.1M | $7.2M | $7.1M | $12.3M | $14.2M | $7.7M | — | — |
| Short-term debt | $14.5M | $7.2M | $2.9M | $2.3M | $1.3M | $3.7M | — | — |
| Total current liabilities | $252.0M | $228.9M | $202.9M | $176.0M | $116.8M | $75.9M | — | — |
| Long-term debt | $265.9M | $279.8M | $280.3M | $225.1M | $157.4M | $362.5M | — | — |
| Total liabilities | $682.9M | $672.0M | $681.0M | $655.1M | $382.1M | $536.9M | — | — |
| Retained earnings | -$808.6M | -$818.3M | -$760.8M | -$572.6M | -$357.1M | -$13.1M | — | — |
| Total equity | $1.52B | $1.45B | $1.43B | $1.52B | $1.55B | $997.8M | -$166.4M | -$109.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $146.2M | $107.3M | -$16.9M | $52.8M | $9.4M | — | $17.0M | — |
| Depreciation and amortisation | $41.6M | $40.7M | $37.4M | $28.9M | $15.1M | — | $3.0M | — |
| Stock-based compensation | $74.7M | $76.2M | $99.4M | $187.4M | $259.4M | — | $54.0K | — |
| Capital expenditure | $36.1M | $21.6M | $40.5M | $79.3M | $94.5M | — | $14.3M | — |
| Investing cash flow | -$36.1M | -$21.6M | -$60.3M | -$139.5M | -$194.1M | — | -$73.4M | — |
| Financing cash flow | -$16.0M | -$9.9M | $47.4M | $47.3M | $313.9M | — | $48.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-170798.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| PRVA | Privia Health Group, Inc. | $2.64B | 114.8x | 22.3% |
| WGS | GeneDx Holdings Corp. | $2.56B | — | 40.0% |
| INNV | InnovAge Holding Corp. | $1.46B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.39B | — | 53.2% |
| PNTG | Pennant Group, Inc. | $1.33B | 45.2x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.18B | 55.9x | 16.3% |
| SRTA | Strata Critical Medical, Inc. | $470.6M | 10.6x | 34.3% |
| DCGO | DocGo Inc. | $39.8M | — | -47.7% |